Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

5 Dec 2024

Optimising Preclinical Studies for Intranasal and Pulmonary Programmes

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
27 Nov 2024

Targeted Aerosol Delivery to NALT Using BiVax Intranasal Atomizer

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
12 Nov 2024

PureHale® & The Future of Fine Mist Dispensers for Upper Airway Treatments

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
28 Oct 2024

Acute Migraine Relief: Nose-to-Brain Delivery with Lipid Nanoparticles

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 27
Back To Top